4.13
+0.22(+5.63%)
Currency In USD
| Previous Close | 3.91 |
| Open | 3.92 |
| Day High | 4.15 |
| Day Low | 3.88 |
| 52-Week High | 6.9 |
| 52-Week Low | 1.69 |
| Volume | 48,698 |
| Average Volume | 80,950 |
| Market Cap | 10.66M |
| PE | -1.32 |
| EPS | -3.13 |
| Moving Average 50 Days | 3.4 |
| Moving Average 200 Days | 2.97 |
| Change | 0.22 |
If you invested $1000 in Creative Medical Technology Holdings, Inc. (CELZ) since IPO date, it would be worth $0.5 as of October 24, 2025 at a share price of $4.13. Whereas If you bought $1000 worth of Creative Medical Technology Holdings, Inc. (CELZ) shares 5 years ago, it would be worth $413 as of October 24, 2025 at a share price of $4.13.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Creative Medical Technology Holdings Congratulates 2025 Nobel Laureates for Regulatory T Cell Breakthroughs
GlobeNewswire Inc.
Oct 07, 2025 1:15 PM GMT
Recent Issuance of U.S. Patents Covering ImmCelz™ — Supercharged Regulatory T Cell Programs in Heart Failure and Type 1 Diabetes Reinforce Creative Medical’s Similar Research FocusPHOENIX, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technolo
Creative Medical Technology Holdings Secures FDA Fast Track Designation for CELZ-201-DDT - Advancing Breakthrough Therapy for Chronic Lower Back Pain
GlobeNewswire Inc.
Aug 13, 2025 1:01 PM GMT
PHOENIX, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a clinical-stage biotechnology company focused on regenerative and immune cellular therapies, today announced that the U.S. Food and Drug Administ
Creative Medical Technology Holdings Receives Notice of Allowance for the Prevention and/or Treatment of Type 1 Diabetes Using Modulated Immune Cells
GlobeNewswire Inc.
Jul 17, 2025 1:15 PM GMT
PHOENIX, July 17, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”), a clinical-stage biotechnology company specializing in regenerative medicine, today announced that it has re